Xenon Pharmaceuticals (XENE) Assets Average (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 13 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.0 billion, up 31.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 31.05% YoY), and the FY2025 annual result was $715.7 million, down 18.81% from the prior year.
• Assets Average rose to $1.0 billion in Q1 2026 per XENE's latest filing, from $620.5 million in the prior quarter.
• Over five years, Assets Average peaked at $1.0 billion in Q1 2026 and troughed at $565.0 million in Q1 2022.
• A 5-year average of $765.4 million and a median of $765.0 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average surged 193.69% in 2022, then dropped 25.45% in 2025.
• A 5-year view of Assets Average shows it stood at $765.0 million in 2022, then gained by 6.92% to $817.9 million in 2023, then declined by 0.11% to $817.0 million in 2024, then slipped by 24.05% to $620.5 million in 2025, then surged by 62.77% to $1.0 billion in 2026.
• Business Quant data shows XENE's Assets Average at $1.0 billion in Q1 2026, $620.5 million in Q4 2025, and $641.1 million in Q3 2025.